Related papers: An Executable Specification of Oncology Dose-Escal…
Prolog is a well known declarative programming language based on propositional Horn formulas. It is useful in various areas, including artificial intelligence, automated theorem proving, mathematical logic and so on. An active research area…
Decision-making in personalized medicine such as cancer therapy or critical care must often make choices for dosage combinations, i.e., multiple continuous treatments. Existing work for this task has modeled the effect of multiple…
Phase I early-phase clinical studies aim at investigating the safety and the underlying dose-toxicity relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider…
We revisit the problem of \textit{online linear optimization} in case the set of feasible actions is accessible through an approximated linear optimization oracle with a factor $\alpha$ multiplicative approximation guarantee. This setting…
Termination properties of actual Prolog systems with constraints are fragile and difficult to analyse. The lack of the occurs-check, moded and overloaded arithmetical evaluation via is/2 and the occasional nontermination of finite domain…
Adaptive Phase 2/3 designs hold great promise in contemporary oncology drug development, especially when limited data from Phase 1 dose-finding is insufficient for identifying an optimal dose. However, there is a general concern about…
Type inference is an application domain that is a natural fit for logic programming (LP). LP systems natively support unification, which serves as a basic building block of typical type inference algorithms. In particular, polymorphic type…
New medical treatment development requires multiple phases of clinical trials. Despite the significant human and financial costs of bringing a drug to market, less than 20% of drugs in testing will make it from the first phase to final…
The primary objective of Phase I oncology trials is to assess the safety and tolerability of novel therapeutics. Conventional dose escalation methods identify the maximum tolerated dose (MTD) based on dose-limiting toxicity (DLT). However,…
It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct…
Logic programming with tabling and constraints (TCLP, tabled constraint logic programming) has been shown to be more expressive and in some cases more efficient than LP, CLP or LP + tabling. Previous designs of TCLP systems did not fully…
Writing specifications for computer programs is not easy since one has to take into account the disparate conceptual worlds of the application domain and of software development. To bridge this conceptual gap we propose controlled natural…
In Oncology, trials evaluating drug combinations are becoming more common. While combination therapies bring the potential for greater efficacy, they also create unique challenges for ensuring drug safety. In Phase-I dose escalation trials…
Positivity violations can complicate estimation and interpretation of causal dose-response curves (CDRCs) for continuous interventions. Weighting-based methods are designed to handle limited overlap, but the resulting weighted targets can…
Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, it is common to divide the study in two stages: i) a first stage in which dose is…
The programming language Prolog makes declarative programming possible, at least to a substantial extent. Programs may be written and reasoned about in terms of their declarative semantics. All the advantages of declarative programming are…
An objective of phase I dose-finding trials is to find the maximum tolerated dose; the dose with a particular risk of toxicity. Frequently, this risk is assessed across the first cycle of therapy. However, in oncology, a course of treatment…
Treatment of cancer has rapidly evolved over time in quite dramatic ways, for example from chemotherapies, targeted therapies to immunotherapies and chimeric antigen receptor T-cells. Nonetheless, the basic design of early phase I trials in…
Transitioning from Phase 2 to Phase 3 in drug development, at a rate of $\approx$40%, is the most stringent among phase transitions (Hay et al. (2014)). Yet, success rate at Phase 3 leading to approval is only $\approx$50% (Arrowsmith…
Runtime repeated recursion unfolding was recently introduced as a just-in-time program transformation strategy that can achieve super-linear speedup. So far, the method was restricted to single linear direct recursive rules in the…